Itopsy 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. Itopsy 200 is commonly prescribed for infections such as aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis, including oropharyngeal and esophageal forms. The capsule formulation ensures optimal bioavailability when administered with food, facilitating effective systemic absorption. Dosage and duration of therapy depend on the type and severity of infection, patient response, and clinical judgment. It is contraindicated in patients with known hypersensitivity to itraconazole or any of its excipients, and caution is advised in individuals with hepatic impairment or congestive heart failure. Potential adverse effects include gastrointestinal disturbances, hepatotoxicity, and rare cardiac events. Drug interactions are significant due to itraconazole’s inhibition of cytochrome P450 3A4 enzymes, necessitating careful review of concomitant medications. Regular monitoring of liver function and clinical status is recommended during therapy. Itopsy 200 Capsule should be used under medical supervision to ensure safety and efficacy in managing fungal infections.